Details of the Drug

General Information of Drug (ID: DMV05CY)

Drug Name

HaNK

Indication

Disease Entry	ICD 11	Status	REF
Merkel cell carcinoma	2C34	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Cell therapy

Cross-matching ID

References

1	ClinicalTrials.gov (NCT03853317) QUILT-3.063: A Phase 2 Study of Combination Therapy With an IL-15 Superagonist (N-803), Off-the-shelf CD16-targeted Natural Killer Cells (haNK), and Avelumab Without Cytotoxic Chemotherapy in Subjects With Merkel Cell Carcinoma (MCC) That Has Progressed on or After Treatment With a Checkpoint Inhibitor. U.S.National Institutes of Health.